Humacyte (NASDAQ:HUMA) Given "Buy" Rating at D. Boral Capital

Key Points

• D. Boral Capital reissued a Buy rating on Humacyte with a $25 price target, while the consensus across analysts is a Moderate Buy with an average target of $7.71.
• Shares fell 12.3% to $0.68 after Q4 results: EPS met expectations at ($0.13) but revenue missed badly at $0.47M versus $1.35M, highlighting near‑term commercialization and cash‑flow risks.
• Humacyte hired Rick McElheny as SVP of Business Development, a strategic addition intended to accelerate partnerships and potential commercialization of its HAV pipeline.

Humacyte (NASDAQ:HUMA - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at D. Boral Capital in a research note issued on Friday,Benzinga reports. They presently have a $25.00 price target on the stock.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a "buy" rating and issued a $3.00 price target on shares of Humacyte in a research report on Monday, December 1st. Benchmark cut their price objective on shares of Humacyte from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, January 21st. Weiss Ratings reissued a "sell (d-)" rating on shares of Humacyte in a research note on Monday, December 29th. UBS Group reaffirmed a "buy" rating on shares of Humacyte in a research report on Monday, December 1st. Finally, BTIG Research cut their price target on Humacyte from $6.00 to $3.00 and set a "buy" rating on the stock in a report on Friday. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Humacyte presently has an average rating of "Moderate Buy" and an average price target of $7.71.

Humacyte Stock Down 12.3%

Shares of HUMA stock traded down $0.10 on Friday, hitting $0.68. The stock had a trading volume of 12,133,637 shares, compared to its average volume of 6,749,416. The company has a quick ratio of 0.90, a current ratio of 1.62 and a debt-to-equity ratio of 2.97. The business has a 50 day moving average price of $1.05 and a 200 day moving average price of $1.29. The company has a market cap of $127.91 million, a PE ratio of -2.94 and a beta of 1.89. Humacyte has a one year low of $0.67 and a one year high of $2.93.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its quarterly earnings data on Friday, March 27th. The company reported ($0.13) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.13). The business had revenue of $0.47 million during the quarter, compared to analysts' expectations of $1.35 million. Research analysts anticipate that Humacyte will post -1.27 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in HUMA. R Squared Ltd purchased a new stake in Humacyte in the fourth quarter valued at about $25,000. Atom Investors LP acquired a new position in shares of Humacyte during the fourth quarter valued at about $25,000. Truist Financial Corp purchased a new position in shares of Humacyte in the 3rd quarter valued at approximately $28,000. Prudential Financial Inc. purchased a new position in shares of Humacyte in the 2nd quarter valued at approximately $28,000. Finally, Financial Advisors Network Inc. acquired a new stake in Humacyte in the 2nd quarter worth approximately $28,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Key Humacyte News

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: Company hired Rick McElheny as SVP of Business Development, bringing experience in corporate development and alliances that could accelerate partnerships and commercialization of Humacyte’s pipeline. Humacyte Appoints Rick McElheny as Senior Vice President of Business Development
• Neutral Sentiment: The full Q4 2025 earnings-call transcript is available for investors who want management’s commentary on clinical progress, collaborations and cash runway; the call provides context but didn’t contain a major new catalyst. Humacyte, Inc. (HUMA) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results: EPS of ($0.13) matched estimates but revenues were $0.47M vs. ~$1.35M expected — a clear miss. Low quarterly sales and modest collaboration revenue reinforce near-term commercialization and cash-flow risks. Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates
• Negative Sentiment: BTIG cut its price target from $6.00 to $3.00 (while retaining a "buy" rating), materially reducing the implied upside and likely weighing on sentiment despite the positive rating. BTIG Lowers Price Target on Humacyte

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company's proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient's own tissue. Humacyte's primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company's lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.